Foamable Composition

a technology of foam and composition, applied in the field of foamable composition, can solve the problems of skin dry cracks, destabilizing foam, complicated foam system,

Inactive Publication Date: 2013-07-25
FOAMIX PHARMACEUTICALS LIMITED
View PDF5 Cites 120 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0040]In certain embodiments, the organic carrier is a combination of a hydrophobic carrier and a polar solvent; or a combination of an emollient and a polar solvent; or a combination of a hydrophobic carrier, an emollient and a polar solvent. Polar solvents may be added to the foam composition for a variety of reasons, such as to increase drug solubilization, promote dermal drug delivery or provide a desired sensory feeling. However, polar solvents tend to dry the skin and impair the integrity of the skin barrier. By contrast, by combining a polar solvent and a hydrophobic carrier, or an emollient or both, unwanted skin barrier damage is reduced. A ratio of 8:1 and 1:4 between the hydrophobic carrier / emollient and the polar solvent is preferred.Film Forming Agent
[0041]The foamable composition of the present invention contains a film forming agent. The film forming agent serves to stabilize the foam composition and to control drug residence in the target organ, thereby limiting the rate of its clearance from the site. The film formation properties of the foamable composition help maintain active ingredients on the site of application by imparting resistance to abrasion or rub-off. Furthermore, in certain cases, the film that is formed promotes the penetration of active agents into the skin (intradermal penetration) and through the skin (transdermal penetration), as it creates an occlusive or semi-occlusive layer at the treatment site.

Problems solved by technology

Foams and, in particular, foam emulsions are complicated systems which do not form under all circumstances.
Changes in foam emulsion composition, such as by the addition of active ingredients may destabilize the foam.
The alcohol promotes fast drying and thereby attempts to address the sticky feeling left by many topical formulations after application; however, alcohols, and in particular the methyl, ethyl and isopropyl alcohols preferred in the '920 patent, are defatting agents and may cause skin to become dry and cracked.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Insect Repellent Composition Containing a Film Forming Polymer

[0171]

Ingredient% w / wDiethyltoluamide25.00Glycerine5.00PEG 4005.00Stearic acid4.00Span 604.00Tween 602.00Dermacryl 79 (film forming agent)0.7Isosearic Acid0.50Triethanolamine0.46Phenonip (preservative)0.25Pemulen TR2 (film forming agent)0.06Propellant (propane and butane)6.00Water47.03100.00

example 2

Insect Repellency Test in Humans

[0172]The efficacy of the foamable composition of Example 1 as repellent against Aedes aegypti mosquitoes was tested under laboratory conditions, in comparison with the same composition without the film forming polymer Dermacryl and Pemulen.

[0173]The mosquitoes used in this work were laboratory-reared, sugar-fed, 3- to 5-days-old adult Aedes aegypti. Before the test, the mosquitoes were starved for 24 h .The test was carried out from 8.30 to 16.30.

[0174]The test was conducted in a room maintained at 23±2° C. Human volunteers were used, whereby one of the repellents was applied to one bare forearm and hand and another formulation to the other forearm and hand. Then, every hour for during the test period, each volunteer put each treated arm into a mosquito cage, containing about 150-200 starved Aedes aegypti adult mosquitoes for 10 minutes. The number of mosquitoes landing on each of the arms was counted during each 10-minute exposure (8 replicas) for a...

example 3

Foamable Composition Containing Aculyn and Pemulen for Treating Atopic Dermatitis

[0177]

Ingredient% w / wMineral Oil3.00Shea Butter2.00Avocado Oil4.00C12-C15 Alkyl Benzoate4.00Cyclomethicone (Dow Corning 245)0.50Stearyl Dimethicone (Dow Corning 2502)2.00Stearic Acid0.80Polyoxyl 2 Stearyl Ether (Brij72)0.75Polyoxyethylene 21 Stearyl Ether (Brij721)1.50Behenyl Alcohol0.40Acrylates / C10-30 Alkylacrilate Crosspolymer0.10(Pemulen TR2, film forming agent)Bis PEG / PPG-18Methyl Ether Dimethyl Silane1.00(Dow Corning 2501, film forming agent)Propylene Glycol3.00Glycerin5.00PEG150 / Stearyl Alcohol / SMDI Copolymer1.00(Aculyn46)Aloe Vera extract0.30Triethanolamine (TEA)0.15Water60.10Disodium EDTA0.10Sodium Hyaluronate (1%)0.50Licorice Extract0.50Alpha Bisabolol0.30Tocopheryl Acetate0.50Allantoin0.50Propane / Butane / Isobutane8.00Total100.00

[0178]The composition of Example 3 contains two film forming agents and a series of active agents that are known to affect skin inflammation, including avocado oil, cyc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
molecular weightaaaaaaaaaa
average primary particle sizeaaaaaaaaaa
Login to view more

Abstract

A foamable composition, includes (1) about 6% to about 70% by weight of at least one organic carrier; (2) about 0.1% to about 5% by weight of at least one surface-active agent; (3) about 0.01% to about 5% by weight of at least one film forming agent; (4) water; and (5) about 3% to about 25% by weight of the total composition of at least one liquefied or compressed gas propellant. The composition is substantially alcohol free and is used in treating, alleviating or preventing a disorder.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation application of U.S. application Ser. No. 11 / 337,747, filed Jan. 23, 2006, which is 1) a continuation-in-part application of International Patent Application No. IB03 / 005527, filed on Oct. 24, 2003, which claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Patent Application Ser. No. 60 / 429,546, filed on Nov. 29, 2002, and claims the benefit of priority under 35 U.S.C. §119(a) to Israeli Patent Application No. 152486, filed Oct. 25, 2002; 2) a continuation-in-part application of U.S. patent application Ser. No. 10 / 911,367, filed on Aug. 4, 2004, which claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Patent Application Ser. No. 60 / 492,385, filed on Aug. 4, 2003; and 3) a continuation-in-part application of U.S. patent application Ser. No. 10 / 922,358, filed Aug. 20, 2004, which claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Patent Application Ser. No. 60 / 497,648, fil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K8/04A61Q19/08A61Q19/02A61Q19/00A61K9/12A61Q17/04A61K
CPCA61K8/046A61K9/122A61Q17/04A61Q19/00A61Q19/02A61Q19/08A61K8/87A61K2800/30A61K8/731A61Q17/02A61K8/736A61K8/8152A61K8/8158A61Q19/007A01N25/16A61K8/34A61K8/345A61K8/42A61K8/922A61K2800/24A61K2800/242A61K2800/244A61K9/0014A61K8/362A61K8/37A61K8/4993A61K8/86A61P9/00A61P23/00A61P29/00A61P31/00A61P37/08
Inventor TAMARKIN, DOVFRIEDMAN, DORONEINI, MEIR
Owner FOAMIX PHARMACEUTICALS LIMITED
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products